The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Is the biology of T-cell malignancies too complex for a single-agent immunotherapy approach?
Yumeng Zhang, MD, Moffitt Cancer Center, Tampa, FL, highlights the biological complexity of T-cell lymphomas and the limitations of single-agent approaches in aggressive subtypes, such as peripheral T-cell lymphoma (PTCL). She emphasizes the need for rational combination strategies that both reduce tumor burden and enhance antitumor immunity, noting that future progress will depend on identifying the optimal agents and timing for these combinations. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
As a T-cell lymphoma doctor, the biology of T-cell lymphoma is very complex, probably even more complex than B-cell biology. And I do agree that for aggressive T-cell lymphoma like PTCL, maybe single-agent therapy or single-agent immune-based therapy are not enough. Because on one side you have to reduce the amount of tumor burden there is, on the other side you have to stimulate the immune system to fight off the cancer, so I think eventually we’re going to see more and more combination therapies come out, but the question is what’s the timing and what are the best agents to combine with...
As a T-cell lymphoma doctor, the biology of T-cell lymphoma is very complex, probably even more complex than B-cell biology. And I do agree that for aggressive T-cell lymphoma like PTCL, maybe single-agent therapy or single-agent immune-based therapy are not enough. Because on one side you have to reduce the amount of tumor burden there is, on the other side you have to stimulate the immune system to fight off the cancer, so I think eventually we’re going to see more and more combination therapies come out, but the question is what’s the timing and what are the best agents to combine with.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
